BREAKTHROUGH IN ALOPECIA

HERE are the facts about ALOPECIA: 

Alopecia areata, commonly referred to as just alopecia, is an autoimmune disorder in which the body attacks its own hair follicles, causing hair to fall out, often in clumps. 

Read more

The National Institute for Health and Care Excellence (NICE) estimates that alopecia areata affects 15 in 10,000 people in the UK. The NICE calculation gives a figure around 100,000 people in the UK currently affected by alopecia. AND in the US approximately 6.8 million people.

Kendall Marcus, M.D., director of the Division of Dermatology and Dentistry in the FDA’s Centre for Drug Evaluation and Research STATES: ‘Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia, today’s approval will help fulfil a significant unmet need for patients with severe alopecia areata.’

BEFORE THIS - there weren't many options for people with the condition: They often relied on steroid injections or unproven creams in an attempt to reverse the condition. 

ADDITIONALLY - People in the US suffering with alopecia have often taken other drugs that may help, such as JAK inhibitors ruxolitinib or tofacitinib, but they are not approved by the FDA for alopecia. That means they can only be prescribed off-label, which insurers often don’t cover and can cost patients as much as $5,000 a month. WHAT. 

This is so good to hear that the FDA has approved such a GAME CHANGER. 

Join the conversation here.

September 2022

BREAKTHROUGH IN ALOPECIA

HERE are the facts about ALOPECIA: 

Alopecia areata, commonly referred to as just alopecia, is an autoimmune disorder in which the body attacks its own hair follicles, causing hair to fall out, often in clumps. 

The National Institute for Health and Care Excellence (NICE) estimates that alopecia areata affects 15 in 10,000 people in the UK. The NICE calculation gives a figure around 100,000 people in the UK currently affected by alopecia. AND in the US approximately 6.8 million people.

Kendall Marcus, M.D., director of the Division of Dermatology and Dentistry in the FDA’s Centre for Drug Evaluation and Research STATES: ‘Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia, today’s approval will help fulfil a significant unmet need for patients with severe alopecia areata.’

BEFORE THIS - there weren't many options for people with the condition: They often relied on steroid injections or unproven creams in an attempt to reverse the condition. 

ADDITIONALLY - People in the US suffering with alopecia have often taken other drugs that may help, such as JAK inhibitors ruxolitinib or tofacitinib, but they are not approved by the FDA for alopecia. That means they can only be prescribed off-label, which insurers often don’t cover and can cost patients as much as $5,000 a month. WHAT. 

This is so good to hear that the FDA has approved such a GAME CHANGER. 

Join the conversation here.

Subscribe To KIT.Journal

Subscribe to our newsletter, The KIT.Journal

A valid email address must be provided.
Ups, something went wrong.
Thank you for signing up. You’ll hear from us soon.